Jacobson Pharma Corporation

Jacobson Pharma Corporation EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Jacobson Pharma Corporation (2633.HK) as of Oct 17, 2026 is 14.73. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 9.62 — a change of 53.19% (higher).

EV/FCF

14.73

YoY

53.19%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Jacobson Pharma Corporation is 2026 14.73 . EV/FCF (Enterprise Value to Free Cash Flow) of Jacobson Pharma Corporation was 2025 9.62 . It decreases by 53.19% higher compared to the previous year.

The Jacobson Pharma Corporation EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
8.59 HKD
Jan 1, 2020
10.50 HKD
Jan 1, 2021
10.29 HKD
Jan 1, 2022
9.67 HKD
Jan 1, 2023
5.09 HKD
Jan 1, 2024
7.75 HKD
Jan 1, 2025
9.62 HKD
Jan 1, 2026
14.73 HKD
The Jacobson Pharma Corporation EV/FCF history
YEAREV/FCFYoY
14.73+53.19%
9.62+24.07%
7.75+52.44%
5.09-47.41%
9.67-6.05%
10.29-1.98%
10.50+22.20%
8.59-56.17%
19.60-52.67%
41.42+32.43%
31.27-297.12%
-15.87-69.29%
-51.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jacobson Pharma Corporation Stock analysis

What does Jacobson Pharma Corporation do? Jacobson Pharma Corporation Ltd, listed on the Hong Kong Stock Exchange under ticker 2633.HK, is a pharmaceutical company operating in the Health Care sector. The company's ISIN is KYG677291067, and it is based in Hong Kong, though the specific city is unknown. Jacobson Pharma provides generic drugs for both public and private sectors, employing 1,789 full-time staff. The company went public via an IPO on September 21, 2016. Its business is structured into two segments: the Generic Drugs segment, which focuses on the development, manufacturing, and distribution of off-patent medicines for various therapeutic uses, and the Branded Healthcare segment, which develops, manufactures, and distributes branded medicines, proprietary Chinese medicines, and health and wellness products. Both segments primarily operate within Hong Kong. The company's website is http://www.jacobsonpharma.com/. Jacobson Pharma Corporation Ltd does not disclose additional details regarding its founding year, key executives, specific product names, or financial figures beyond the provided data. The company's operations are centered around pharmaceutical manufacturing and distribution, emphasizing generic and branded healthcare solutions in the Hong Kong market. Jacobson Pharma Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jacobson Pharma Corporation stock

EV/FCF (Enterprise Value to Free Cash Flow) of Jacobson Pharma Corporation is 14.73 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Jacobson Pharma Corporation changed from 9.62 to 14.73, representing a 53.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Jacobson Pharma Corporation since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Jacobson Pharma Corporation with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Jacobson Pharma Corporation

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Jacobson Pharma Corporation